Skip to main content
. Author manuscript; available in PMC: 2023 Dec 6.
Published in final edited form as: Cell Metab. 2022 Oct 14;34(12):1932–1946.e7. doi: 10.1016/j.cmet.2022.09.019

Figure 7. Auranofin restores eWAT lipolytic competence.

Figure 7.

(A) eWAT Adrb3 in wild-type mice fed high fat diet (WT+HFD, n=4/group) and LepR KO mice (n=5/group) treated with auranofin (1 mg/kg) or vehicle. RNA-Seq data shown as reads per kb million (RPKM). (B) Serum leptin and (C) ADRB3 and HSL expression in subcutaneous WAT of lean and obese persons (n=5/group). (D) Fasting free fatty acids (WT+HFD vehicle n=5, auranofin n=9; LepR KO vehicle n=4, auranofin n=5). (E) eWAT ex vivo Oxygen consumption rate (OCR, n=12/group) after 100 nM auranofin or vehicle (DMSO). (F) Glycerol release from wild-type and beta-less (Adrb1/Adrb2/Adrb3 KO) eWAT cultured ex vivo with 100 nM auranofin or vehicle (DMSO) +/− isoproterenol (10 μM) for 2 hours (n=3/group). (G) Immunoblots of eWAT lysates from (F) probed and quantified (n=4/group) for phospho-HSL and total HSL. (H) Glycerol release from eWAT 2 hours after 100 nM auranofin or vehicle (DMSO) and isoproterenol (WT+HFD n=12/group; LepR KO n=8/group). (I) eWAT leptin secretion into the media two hours after vehicle, isoproterenol (1 μM), or isoproterenol (1 μM) plus 100 nM auranofin (n=7/group). (J) Immunofluorescent staining and quantification of macrophages using Mac2 (n=6/group, scale=250 μm) and CD68 (n=3/group, scale=100 μm). (K) Immunoblots of eWAT lysates probed for tyrosine hydroxylase (TH) with corresponding densitometry.

All data are mean ± SEM. *p<0.05, #p<0.10 by unpaired t-test (A, RNA-Seq; B-E), one-way ANOVA with Tukey’s multiple comparisons test (I), and two-way ANOVA with Tukey’s multiple comparisons test: (A, qPCR; F; G, pHSL/HSL; H; J; K)